US Stock MarketDetailed Quotes
KAPA Kairos Pharma
- 1.480
- +0.010+0.69%
Close Oct 18 16:00 ET
- 1.580
- +0.100+6.75%
Post 20:02 ET
19.01MMarket Cap-8222P/E (TTM)
1.530High1.330Low26.67KVolume1.490Open1.470Pre Close39.10KTurnover1.72%Turnover RatioLossP/E (Static)12.84MShares4.00052wk High-21.45P/B2.29MFloat Cap1.22052wk Low--Dividend TTM1.55MShs Float4.000Historical High--Div YieldTTM13.60%Amplitude1.220Historical Low1.465Avg Price1Lot Size
Kairos Pharma Stock Forum
Sign in to post a comment
$Kairos Pharma (KAPA.US)$ wow this stock direction is only down😂😂😂
1
$Kairos Pharma (KAPA.US)$ I CANT WAIT TO SELL THIS CRAP.. what a useless everything
$Kairos Pharma (KAPA.US)$ Mehn.. RESERVE SPLIT loading already. thats how they drop
$Kairos Pharma (KAPA.US)$ So thats it? a trap
$Kairos Pharma (KAPA.US)$ Reuters· 1 min ago
Kairos Pharma Enters Agreement With Precheck Health Services to Develop Biomarkers to Identify Patients Responsive to Env105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients
Kairos Pharma Enters Agreement With Precheck Health Services to Develop Biomarkers to Identify Patients Responsive to Env105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients
2
$Kairos Pharma (KAPA.US)$
Kairos Pharma Enters Agreement With Precheck Health Services to Develop Biomarkers to Identify Patients Responsive to Env105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients
Kairos Pharma (NYSE American: KAPA)has entered a collaboration with PreCheck Health Services Inc. to develop companion biomarkers for its cancer therapy, ENV105, targeting prostate and lung cancers. The partnership aims to enhance patient screening and therapy monitoring for ...
Kairos Pharma Enters Agreement With Precheck Health Services to Develop Biomarkers to Identify Patients Responsive to Env105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients
Kairos Pharma (NYSE American: KAPA)has entered a collaboration with PreCheck Health Services Inc. to develop companion biomarkers for its cancer therapy, ENV105, targeting prostate and lung cancers. The partnership aims to enhance patient screening and therapy monitoring for ...
1
2
$Genelux (GNLX.US)$ 5 analysts have this as a buy. Also close to a gap up but could take a few days to reach that gap but will be worth it.
$Healthy Choice Wellness (HCWC.US)$ 2nd day rally. Im in at 5.15.
$Kairos Pharma (KAPA.US)$ Also. Im in at 2.25.
$Knightscope (KSCP.US)$ Extremely high short interest after RS. Buying in at open with a goal of 7.75.
Plan on being in the green and up 40% at the end of the day.
$Healthy Choice Wellness (HCWC.US)$ 2nd day rally. Im in at 5.15.
$Kairos Pharma (KAPA.US)$ Also. Im in at 2.25.
$Knightscope (KSCP.US)$ Extremely high short interest after RS. Buying in at open with a goal of 7.75.
Plan on being in the green and up 40% at the end of the day.
11
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
72553206 : that would be nuts, I'm in the long hold. Sadly at $2.2/share